clinical trials glp-1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy The transformative breakthroughs in GLP-1

The key milestones include: exenatide approval (2005), liraglutide approval (2010), semaglutide injection approval (2017), oral semaglutide with SNAC approval (2019), orforglipron cryo-EM structure published (2020), orforglipron Phase 2 results in NEJM (2023), orforglipron Phase 3 ATTAIN-1 results in NEJM (2025), and FDA regulatory submission (2025)

As a widely used healthcare guideline for opened multi-dose vials, vials are commonly dated and discarded within 28 days after first puncture unless the manufacturer states a different timeframe

No Wheat, Gluten, Soybeans, Dairy, Egg, Fish/Shellfish, Peanuts/Tree Nuts or Sesame

Accepted April 30, 2026

Mohs excision has also been used for treatment of melanoma in situ, but even with Mohs excision clear margins are still uncertain due to difficulty of seeing atypical melanocytes on frozen sections